Viatris Announces Launch of First Bioequivalent Generic Version of Copaxone® 20 mg/mL Once-Daily in Canada

CNW Group04-15

New generic Multiple Sclerosis treatment option, PrGlatiramer Acetate Injection 20 mg/mL for once-daily injection, available for one of the largest MS populations in the world ETOBICOKE, ON, April 15,...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2427071184?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/RNTAQPcQGOgFeb9lROBGAQ--~B/aD0xMTI7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/cnwgroup.com/c03b6c5b724244b6bb2d566254fd974b","is_english":true,"pubTime":"2024-04-15 18:59","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2427071184","market":"us","top_or_hot":-1,"title":"Viatris Announces Launch of First Bioequivalent Generic Version of Copaxone® 20 mg/mL Once-Daily in Canada","media":"CNW Group","content":"<div>\n<p>New generic Multiple Sclerosis treatment option, PrGlatiramer Acetate Injection 20 mg/mL for once-daily injection, available for one of the largest MS populations in the world\nETOBICOKE, ON, April 15,...</p>\n\n<a href=\"https://finance.yahoo.com/news/viatris-announces-launch-first-bioequivalent-105900679.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Viatris Announces Launch of First Bioequivalent Generic Version of Copaxone® 20 mg/mL Once-Daily in Canada</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nViatris Announces Launch of First Bioequivalent Generic Version of Copaxone® 20 mg/mL Once-Daily in Canada\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-15 18:59 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/viatris-announces-launch-first-bioequivalent-105900679.html><strong>CNW Group</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>New generic Multiple Sclerosis treatment option, PrGlatiramer Acetate Injection 20 mg/mL for once-daily injection, available for one of the largest MS populations in the world\nETOBICOKE, ON, April 15,...</p>\n\n<a href=\"https://finance.yahoo.com/news/viatris-announces-launch-first-bioequivalent-105900679.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4127","symbol_name":"投资银行业与经纪业","start_time":0,"source_url":"https://finance.yahoo.com/news/viatris-announces-launch-first-bioequivalent-105900679.html","article_id":"2427071184","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/RNTAQPcQGOgFeb9lROBGAQ--~B/aD0xMTI7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/cnwgroup.com/c03b6c5b724244b6bb2d566254fd974b"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2427071184","pubTimestamp":1713178740,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"New generic Multiple Sclerosis treatment option, PrGlatiramer Acetate Injection 20 mg/mL for once-daily injection, available for one of the largest MS populations in the world. ETOBICOKE, ON, April 15, 2024 /PRNewswire/ -- Viatris Inc. , a global healthcare company, today announced the launch in Canada of PrGlatiramer Acetate Injection 20 mg/mL for once-daily injection, the first generic bioequivalent version of Teva's Copaxone 20 mg/mL, indicated for the treatment of patients with Relapsing-Remitting Multiple Sclerosis , a chronic inflammatory disease of the central nervous system.Viatris Canada's Country Manager Jeffrey Long commented, \"The launch of Glatiramer Acetate Injection 20 mg/mL, the first bioequivalent generic for Copaxone 20 mg/mL, marks another significant milestone for Viatris Canada, reinforcing our proven capabilities in bringing complex and difficult-to-manufacture products to market, and furthering our commitment to providing access to high quality medicines. MS Cana","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4127":"投资银行业与经纪业","LU1839511570.USD":"WELLS FARGO GLOBAL FACTOR ENHANCED EQUITY \"I\" (USD) ACC","BK4583":"猴痘概念","LU0098860793.USD":"FRANKLIN INCOME \"A\" INC","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","LU1162221912.USD":"FRANKLIN INCOME \"A\" (USD) ACC","BK4585":"ETF&股票定投概念","BK4534":"瑞士信贷持仓","VTRS":"Viatris Inc.","BK4007":"制药","LU0320765646.SGD":"FTIF - Franklin Income A MDIS SGD-H1","LU1363072403.SGD":"Fidelity Global Financial Services A-ACC-SGD","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","LU0106831901.USD":"贝莱德世界金融基金A2","BK4588":"碎股","LU2087621335.USD":"ALLSPRING GLOBAL FACTOR ENHANCED EQUITY \"A\" (USD) ACC","LU0971096721.USD":"富达环球金融服务 A","LU1074936037.SGD":"JPMorgan Funds - US Value A (acc) SGD","BK4581":"高盛持仓","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","BK4504":"桥水持仓","LU1668664300.SGD":"Blackrock World Financials A2 SGD-H"},"translate_title":"Viatris宣布在加拿大推出首个生物等效的科帕松®仿制药，每天一次，每次20毫克/毫升","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VTRS":0.9},"content_text":"New generic Multiple Sclerosis treatment option, PrGlatiramer Acetate Injection 20 mg/mL for once-daily injection, available for one of the largest MS populations in the world\nETOBICOKE, ON, April 15, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced the launch in Canada of PrGlatiramer Acetate Injection 20 mg/mL for once-daily injection, the first generic bioequivalent version of Teva's Copaxone® 20 mg/mL, indicated for the treatment of patients with Relapsing-Remitting Multiple Sclerosis (RMMS), a chronic inflammatory disease of the central nervous system.\nViatris Canada's Country Manager Jeffrey Long commented, \"The launch of Glatiramer Acetate Injection 20 mg/mL, the first bioequivalent generic for Copaxone® 20 mg/mL, marks another significant milestone for Viatris Canada, reinforcing our proven capabilities in bringing complex and difficult-to-manufacture products to market, and furthering our commitment to providing access to high quality medicines. MS Canada estimates 90,000 Canadians are living with Multiple Sclerosis—one of the highest rates of MS in the world.i Because of this high prevalence, and because MS affects each person differently, there is a need for a range of medicines to help manage the symptoms of the disease and other medical conditions that are commonly associated with MS.\"\nGlatiramer Acetate Injection 20 mg/mL for once daily injection was approved as a therapeutic equivalent to Copaxone® 20 mg/mL. Viatris generated bioequivalency and characterization data on this product, formulated to have the same dosage form, route of administration and strength as the branded counterpart. Glatiramer Acetate Injection 20 mg/mL is available by prescription only.ii\nA comprehensive patient support program, VIATRIS ADVOCATE™, offers services for patients including reimbursement navigation, financial assistance for eligible patients, injection training and on-going support from MS-experienced nurses.\nFor more information, please consult the Glatiramer Acetate Product Monograph at: https://pdf.hres.ca/dpd_pm/00072479.PDF\nAbout Viatris Viatris Inc. (NASDAQ: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, we provide access at scale, currently supplying high-quality medicines to approximately 1 billion patients around the world annually and touching all of life's moments, from birth to the end of life, acute conditions to chronic diseases. With our exceptionally extensive and diverse portfolio of medicines, a one-of-a-kind global supply chain designed to reach more people when and where they need them, and the scientific expertise to address some of the world's most enduring health challenges, access takes on deep meaning at Viatris. We are headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India. Learn more at viatris.com and investor.viatris.com, and connect with us on LinkedIn, Instagram, YouTube and X (formerly Twitter).\n\n\n\n\n\n\n\n\n\n\n\ni https://mscanada.ca/about-ms#:~:text=Canada%20has%20one%20of%20the,are%20diagnosed%20with%20MS%20everyday \n\n\nii https://pdf.hres.ca/dpd_pm/00072479.PDF \n\n\n\n\n\n\n\n\n\nSOURCE Viatris Inc.","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2427071184"}